低剂量率<sup>125</sup>I近距离放疗治疗中年男性局限性前列腺癌的疗效及风险因素研究

佟凯军; 刘大振; 汤坤龙; 杨长海

doi:10.13201/j.issn.1001-1420.2021.05.004

低剂量率¹²⁵I近距离放疗治疗中年男性局限性前列腺癌的疗效及风险因素研究

- 1. 解放军第九八三医院泌尿外科(天津, 300000);
- 2. 天津医科大学总医院泌尿外科

详细信息

通讯作者: 佟凯军,E-mail:tongjj@tom.com

中图分类号: R737.25

收稿日期: 2020-04-27

Low dose rate ¹²⁵I brachytherapy for localized prostate cancer in middle-aged men

- 1. Department of Urology, the 983 Hospital of PLA, Tianjin, 300000, China;
- 2. Department of Urology, Tianjin Medical University General Hospital

More Information

Corresponding author: TONG Kaijun, E-mail: tongjj@tom.com

Received Date: 27 April 2020

摘要

摘要: 目的:研究低剂量率¹²⁵I近距离放疗治疗中年男性局限性前列腺癌患者的疗效及风险因素。方法:选择106例局限性前列腺癌的中年男性患者为研究对象,采用低剂量率¹²⁵I近距离放疗治疗。术后进行前列腺特异性抗原(PSA)及影像学监测,对粒子分布情况和剂量进行评估,并评估其不良事情、局部复发情况和PSA反弹情况,同时分析局部复发和PSA反弹的相关危险因素。结果:本研究患者术前PSA为(14.39±5.11) ng/mL,术后PSA最低值为(1.02±0.84) ng/mL,达PSA最低值平均时间为13.9个月,前列腺D90为(160±38.3) Gy,前列腺V100为(94.3±9.2) cc,移植体积为(33.7±15.1) cc。本研究患者的中位随访时间为66个月,5年局部无复发生存率、无病生存率和总生存率分别为95.28%、94.33%和92.45%。总体不良反应发生率为19.81%,以尿路刺激症状发生率(11.32%)最高。单因素分析结果显示,活检阳性率至少为50%、中度危险、新辅助激素治疗、移植前V100、无反弹发生是局部复发的危险因素,在随访期间未达到PSA<0.5 ng/mL的激素原发性患者也有较高的局部复发风险。多变量Cox分析结果显示,“至少50%活检阳性”(HR=1.02,95%CI:1.01~1.03,P=0.02)和“反弹”(HR=11.59,95%CI:1.46~91.73,P=0.02)这两个变量显著影响局部复发。35例(33.02%)患者出现PSA反弹,多变量Cox分析结果显示,较年轻的患者(HR=0.99,95%CI:0.85~0.98,P=0.01)和接受较低的治疗活度(HR=0.04,95%CI:0~0.74,P=0.03)的患者出现反弹的概率较高。结论:对中年男性局限性前列腺癌患者来说,低剂量率¹²⁵I近距离放疗是一种有效的低危原发性治疗方案,在中危局限性前列腺癌中也应予以考虑。
- 低剂量率¹²⁵I近距离放疗 /
- 局限性前列腺癌 /
- 局部无复发率 /
- PSA反弹 /
- 危险因素
Abstract: Objective: To study the efficacy and risk factors of low dose rate ¹²⁵I brachytherapy for localized prostate cancer in middle-aged men.Methods: One hundred and six middle-aged male patients with localized prostate cancer were selected as the study subjects and treated with low dose rate ¹²⁵I brachytherapy. After the operation, prostate specific antigen(PSA) and imaging monitoring were carried out to evaluate the particle distribution and dose, as well as the adverse events, local recurrence and PSA rebound. Meanwhile, the risk factors of local recurrence and PSA bounce were analyzed.Results: In this study, the PSA was(14.39±5.11) ng/mL before operation. The lowest PSA was(1.02±0.84) ng/mL after operation, and the average time to reach the lowest PSA was 13.9 months. The prostate D90 was(160.0±38.3) Gy, and the prostate V100 was(94.3±9.2) cc. The transplantation volume was(33.7±15.1) cc. The median follow-up time was 66 months. The 5-year local recurrence free survival rate, disease-free survival rate and total survival rate were 95.28%, 94.33% and 92.45%, respectively. The overall incidence of adverse reactions was 19.81%, with the highest incidence of urinary tract irritation(11.32%). Univariate analysis showed that the positive rate of biopsy was at least 50%, and moderate risk, neoadjuvant hormone therapy, V100 before transplantation and PSA bounce were the risk factors of local recurrence. The patients who did not reach PSA value <0.5 ng/mL during the follow-up period also had a higher risk of local recurrence. Multivariate Cox analysis showed that "at least 50% biopsy positive"(HR=1.02, 95%CI: 1.01-1.03, P=0.02) and "PSA bounce"(HR=11.59, 95%CI: 1.46-91.73, P=0.02) significantly affected local recurrence. Younger patients(HR=0.99, 95%CI: 0.85-0.98, P=0.01) and those treated with a lower activity per volume(HR=0.04, 95%CI: 0-0.74, P=0.03) had a higher chance of developing a bounce in the Cox model.Conclusion: For middle-aged male patients with localized prostate cancer, low dose rate ¹²⁵I brachytherapy is an effective and low-risk primary treatment plan, which should also be considered in the medium-risk limited prostate cancer.
- low dose rate 125I brachytherapy /
- localized prostate cancer /
- local recurrence free rate /
- PSA bounce /
- risk factors

HTML全文

参考文献(22)

[1]	雷钧皓,陈勇吉.根治性前列腺切除术和放射疗法治疗高危前列腺癌的研究进展[J].中华男科学杂志,2015,21(7):663-666.
[2]	Johns LE,Houlston RS.A systematic review and meta-analysis of familial prostate cancer risk[J].BJU Int,2003,91(9):789-794.
[3]	贾鹏飞,周晓曦,季斌,等.前列腺癌近距离照射联合外照射与单纯外照射疗效与安全性Meta分析[J].中华放射肿瘤学杂志,2019,28(7):509-513.
[4]	Grimm P,Billiet I,Bostwick D,et al.Comparative analysis of prostate-specific antigen free survival outcomes for patients with low,intermediate and high risk prostate cancer treatment by radical therapy.Results from the Prostate Cancer Results Study Group[J].BJU Int,2012,109(s1):22-29.
[5]	D'Amico AV,Whittington R,Malkowicz SB,et al.Biochemical outcome after radical prostatectomy,external beam radiation therapy,or interstitial radiation therapy for clinically localized prostate cancer[J].JAMA,1998,280(11):969-974.
[6]	朱寅杰,王艳青,潘家骅,等.前列腺癌根治标本提示神经周围侵犯对预测前列腺癌进展和预后的价值[J].中华外科杂志,2016,54(3):217-221.
[7]	Mazeron R,Bajard A,Montbarbon X,et al.Permanent 125I-seed prostate brachytherapy:early prostate specific antigen value as a predictor of PSA bounce occurrence[J].Radiat Oncol,2012,7:46.
[8]	Burri RJ,Ho AY,Forsythe K,et al.Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer[J].Int J Radiat Oncol Biol Phys,2010,77(5):1315-1321.
[9]	Alfonso GP,Juanita C,Jette B,et al.Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged
[10]	Dickinson PD,Malik J,Mandall P,et al.Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK[J].BJU Int,2014,113(5):748-753.
[11]	Lazarev S,Thompson MR,Stone NN,et al.Low-dose-rate brachytherapy for prostate cancer:outcomes at>10 years of follow-up[J].BJU Int,2018,121(5):781-790.
[12]	Kindts I,Stellamans K,Billiet I,et al.125I brachytherapy in younger prostate cancer patients:Outcomes in low-and intermediate-risk disease[J].Strahlenther Onkol,2017,193(9):707-713.
[13]	Kollmeier MA,Fidaleo A,Pei X,et al.Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer[J].BJU Int,2013,111(8):1181-1182.
[14]	张峰波,杜源,邵强,等.低剂量率近距离放射治疗局限性低/中危前列腺癌133例报告[J].北京大学学报(医学版),2015,47(4):611-614.
[15]	严维刚,周智恩,周毅,等.局限性中高危前列腺癌近距离治疗联合内分泌治疗和外放疗的疗效分析[J].中华泌尿外科杂志,2017,38(6):442-447.
[16]	Hayashi N,Izumi K,Sano F,et al.Ten-year outcomes of I125low-dose-rate brachytherapy for clinically localized prostate cancer:a single-institution experience in Japan[J].World J Urol,2015,33(10):1519-1526.
[17]	Wilson C,Waterhouse D,Lane SE,et al.Ten-year outcomes using low dose rate brachytherapy for localised prostate cancer:An update to the first Australian experience[J].J Med Imag Radiat Oncol,2016,60(4):531-538.
[18]	Caloglu M,Ciezki J.Prostate-specific antigen bounce after prostate brachytherapy:review of a confusing phenomenon[J].Urology,2009,74(6):1183-1190.
[19]	Engeler DS,Schwab C,Thöni AF,et al.PSA bounce after 12 I-brachytherapy for prostate cancer as a favorable prognosticator[J].Strahlenther Onkol,2015,191(10):787-791.
[20]	Chao MW,Grimm P,Yaxley J,et al.Brachytherapy:state-of-the-art radiotherapy in prostate cancer[J].BJU Int,2015,116 Suppl 3:80-88.
[21]	Wolff RF,Ryder S,Bossi A,et al.A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer[J].Eur J Cancer,2015,51(16):2345-2367.
[22]	Zelefsky MJ,Poon BY,Eastham J,et al.Longitudinal assessment of quality of life after surgery,conformal brachytherapy,and intensity-modulated radiation therapy for prostate cancer[J].Radiother Oncol,2016,118(1):85-91.